FNCH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FNCH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Finch Therapeutics Group's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $14.22 Mil. Finch Therapeutics Group's Total Assets for the quarter that ended in Jun. 2024 was $45.58 Mil.
The historical rank and industry rank for Finch Therapeutics Group's Equity-to-Asset or its related term are showing as below:
During the past 5 years, the highest Equity to Asset Ratio of Finch Therapeutics Group was 0.94. The lowest was -0.58. And the median was 0.51.
The historical data trend for Finch Therapeutics Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Equity-to-Asset | -0.58 | -0.58 | 0.90 | 0.59 | 0.41 |
Finch Therapeutics Group Quarterly Data | |||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.42 | 0.43 | 0.41 | 0.38 | 0.31 |
For the Biotechnology subindustry, Finch Therapeutics Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Finch Therapeutics Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 22.886 | / | 55.373 | |
= | 0.41 |
Finch Therapeutics Group's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as
Equity to Asset (Q: Jun. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 14.219 | / | 45.576 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (OTCPK:FNCH) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Finch Therapeutics Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffery A Smisek | director | 1600 SMITH STREET, HQSEO, HOUSTON TX 77002 |
Susan E Graf | director | 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Lance E Thibault | officer: Chief Financial Officer | |
Matthew P. Blischak | officer: Chief Executive Officer | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143 |
Joseph Vittiglio | officer: Chief Business & Legal Officer | C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145 |
Marc Blaustein | officer: Chief Operating Officer | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143 |
Domenic J Ferrante | director | BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116 |
Samuel A Hamood | director | C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661 |
Joanne L. Viney | director | C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Nicholas Haft | director | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143 |
Christian H. Lange | director | 28 HAVEMEYER PLACE, GREENWICH CT 06830 |
Crestovo Investor Llc | director, 10 percent owner | 28 HAVEMEYER PLACE, GREENWICH CT 06830 |
Gregory D Perry | officer: Chief Financial Officer | C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451 |
Chris Shumway | director, 10 percent owner | 28 HAVEMEYER PLACE, GREENWICH CT 06830 |
Zain Kassam | officer: Chief Medical Officer | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143 |
From GuruFocus
By sperokesalga sperokesalga • 04-18-2023
By Value_Insider Value_Insider • 11-10-2022
By Ds*** Ds*** • 09-01-2022
By GuruFocusNews GuruFocusNews • 06-18-2022
By sperokesalga sperokesalga • 03-23-2023
By Value_Insider Value_Insider • 11-09-2022
By PurpleRose PurpleRose • 08-25-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Marketwired • 10-21-2024
By sperokesalga sperokesalga • 04-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.